Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. (NYSE: HIMS) is a health and wellness platform that regularly issues news about its digital care offerings, new specialties, and international growth. Company press releases highlight how the Hims and Hers brands use technology to connect customers with personalized care, with updates that span weight management, women’s health, labs and diagnostics, and broader platform developments.
Recent news has focused heavily on weight loss and metabolic health. Hims & Hers has launched a comprehensive Weight Loss Programme in the UK, including the official introduction of the Hers platform there, giving eligible women access to doctor-designed GLP‑1 treatment plans and holistic support for nutrition, movement, and sleep. In Canada, the company is entering the market through the acquisition of Livewell, a digital health platform focused on weight loss treatment, with plans to roll out an accessible, comprehensive weight loss program for Canadian customers.
Another key news theme is women’s health. The Hers platform has introduced a menopause and perimenopause specialty that offers eligible women access to treatment plans tailored to their health history and preferences, including prescription options such as estradiol and progesterone when deemed appropriate by licensed providers. News coverage also includes the launch of Labs, a testing experience that measures biomarkers across areas like heart health, metabolism, hormones, inflammation, and stress, pairing results with doctor-developed action plans.
Investors and followers of HIMS news will also see announcements about strategic acquisitions, such as the definitive agreement to acquire YourBio Health and its virtually painless TAP blood sampling technology, as well as corporate updates like share repurchase authorizations, financial results, leadership appointments, and facility investments. This news page aggregates these developments so readers can monitor how Hims & Hers is expanding its digital health platform, adding new capabilities, and executing its strategy across the United States, Europe, and Canada.
Hims & Hers Health, a telehealth platform (NYSE: HIMS), will conduct its virtual annual shareholders' meeting on June 17, 2021, at 10:00 a.m. PT.
A live audio webcast will be available on the company’s investor site. Shareholders are invited to participate via this link and must follow the proxy statement procedures to submit questions and vote.
Hims & Hers, established in November 2017, offers accessible healthcare services across various specialties, promoting quality care for mental, sexual, and dermatological health.
Hims & Hers posted impressive Q1 2021 results, achieving 74% revenue growth to $52.3 million, and a 95% increase in gross profit, which yielded a 77% gross margin. The company reported nearly 391,000 subscriptions, up 80% year-over-year. Despite these gains, net loss widened to $(51.4) million, largely due to one-time expenses from the Oaktree merger. Looking ahead, guidance for Q2 2021 forecasts revenue between $55 million and $57 million, with full year expectations set at $221 million to $227 million.
Hims & Hers Health, Inc. (NYSE: HIMS) announced it will restate its 2019 and 2020 consolidated financial statements following SEC guidance regarding SPAC-related warrant accounting. This restatement affects Oaktree Acquisition Corp.'s (OAC) financials, reclassifying warrants as liabilities instead of equity. Hims & Hers anticipates a non-cash expense of less than $5 million and a warrant liability of $30-$35 million as of March 31, 2021. The company asserts that liquidity, cash flows, and revenues remain unaffected by this adjustment.
Hims & Hers Health, Inc. reported strong financial results for Q4 and the full year 2020, showing an 80% year-over-year revenue growth. Q4 revenue reached $41.5 million, a 67% increase from Q4 2019. The company's gross margin also improved to 77% in Q4. While the net loss narrowed to $(5.2) million for Q4, total net loss for 2020 was $(18.1) million, down from $(72.1) million in 2019. Outlook for 2021 anticipates revenue between $195 million to $205 million, with Adjusted EBITDA losses of $(35) million to $(45) million.
Hims & Hers Health, Inc. has appointed Andrea Perez and Ambar Bhattacharyya to its Board of Directors. As the company navigates a critical moment in telehealth post-COVID-19, both leaders bring valuable experience. Perez, currently at Nike, has expertise in scaling consumer businesses, while Bhattacharyya offers a decade of healthcare investment experience. Their appointments aim to enhance access to affordable healthcare, aligning with Hims & Hers' goal to modernize healthcare delivery. The company is traded on NYSE under the symbol 'HIMS' and aims to bridge the gap in consumer healthcare.
Hims & Hers Health, a telehealth platform, will participate in the Citi 2021 Healthcare Services Conference on February 25, 2021, at 3:20 p.m. E.T. CEO Andrew Dudum will lead a fireside chat during the event. Their services cover primary care, mental health, sexual health, and dermatology across all 50 states. Launched in November 2017, Hims & Hers offers accessible and affordable healthcare solutions. The audio webcast and related materials will be available online.
Hims & Hers Health, Inc. (NYSE: HIMS) will release its fiscal fourth quarter and full year 2020 financial results on March 18, 2021, after market close. A conference call will follow at 5:00 p.m. E.T. Investors can join by dialing (833) 900-2256 for U.S. participants or (236) 714-2727 for international participants, using conference ID #3380049. The call will also be available via a live audio webcast, and a replay will be accessible shortly after the event. Hims & Hers is a telehealth platform, providing access to licensed healthcare professionals across numerous medical conditions.